LILLY DRN

Zepbound copycats remain online despite FDA ban

Read more

Jim Cramer’s 6 favorite stocks now, plus updates on rest of portfolio

Read more

FDA says Wegovy and Ozempic shortage resolved; Hims & Hers stock falls

Read more

Trump health care plan likely good for pharmaceutical companies

Read more

Medicare drug price negotiations list includes Ozempic

Read more

Eli Lilly LLY cuts 2024 revenue outlook on weight loss drugs

Read more

High-cost weight loss drugs boost nutrition counseling with employers

Read more

Medicare can cover Eli Lilly’s Zepbound for sleep apnea: Health Department

Read more

Investing Club’s Q3 2024 Earnings Report Card

Read more

FDA Zepbound shortage ends, impacts patients, compounding pharmacies

Read more